Indoximod

DRUG10 trials

Conditions

Diffuse Intrinsic Pontine GliomaEpendymomaGlioblastomaGlioblastoma MultiformeGliomaGliosarcomaMalignant Brain TumorMedulloblastoma

Phase 1

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

CompletedNCT02052648

NewLink Genetics CorporationGlioblastoma Multiforme, Glioma, Gliosarcoma +1

Start: 2014-03-31End: 2019-06-20Updated: 2024-03-27

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

CompletedNCT02073123

NewLink Genetics CorporationMetastatic Melanoma, Stage III Melanoma, Stage IV Melanoma

Start: 2014-07-01End: 2019-07-03Updated: 2026-05-29

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

CompletedNCT02077881

NewLink Genetics CorporationMetastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer

Start: 2014-08-01End: 2018-10-17Updated: 2026-04-03

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

TerminatedNCT02460367

NewLink Genetics CorporationNon-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent, Progression of Non-small Cell Lung Cancer

Start: 2016-01-31End: 2021-01-13Updated: 2022-04-06

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

CompletedNCT02502708

NewLink Genetics CorporationDiffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma Multiforme +5

Start: 2015-10-31End: 2020-02-28Updated: 2020-06-04

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

RecruitingNCT05106296

Theodore S. JohnsonEpendymoma, Glioblastoma, Medulloblastoma +1

Start: 2022-02-08End: 2028-09-30Target: 37Updated: 2026-01-09

Phase 2

Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

CompletedNCT01560923

Masonic Cancer Center, University of MinnesotaMetastatic Prostate Cancer

Start: 2012-10-01End: 2018-12-12Updated: 2020-04-03

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

CompletedNCT01792050

NewLink Genetics CorporationMetastatic Breast Cancer

Start: 2013-02-28End: 2017-07-07Updated: 2020-05-28

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma

TerminatedNCT03301636

NewLink Genetics CorporationMelanoma

Start: 2017-12-08End: 2019-11-04Updated: 2022-09-27

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

Active, not recruitingNCT04049669

Theodore S. JohnsonDiffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma +1

Start: 2019-10-02End: 2027-10-02Updated: 2026-01-08

Neuro-Oncology2025-11-01

IMMU-09. PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH CHILDHOOD BRAIN CANCER: INTERIM ANALYSIS OF THE GCC1949 STUDY (NCT04049669)

Neuro-Oncology2024-06-182 citations

Effect of indoximod-based chemo-immunotherapy in patients with pediatric brain tumors on activation and clonal proliferation of a circulating population of early non-exhausted stem-like CD8+ T cells whose on-treatment expansion is predictive of long-term outcome.

Journal of Clinical Oncology2024-06-01

Repurposing ibrutinib for chemo-immunotherapy in a phase 1b study of ibrutinib with indoximod plus metronomic cyclophosphamide and etoposide for patients with childhood brain cancer.

Journal of Clinical Oncology2024-06-01

Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial

Neuro-Oncology2023-09-1633 citations

Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.

2023-08-1214 citations

Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

Clinical Cancer Research2023-08-0310 citations

HGG-28. INTERIM ANALYSIS OF THE GCC1949 PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS

Neuro-Oncology2023-06-01

Abstract LB200: Indoximod or ibrutinib/indoximod based clinical chemo-immunotherapy drives conversion of extra-tumoral circulating stem-like precursor CD8+ T cells into clonally expanded, rejuvenated effector cells

Cancer Research2023-04-14

CTIM-32. FIRST-IN-CHILDREN PHASE 1 TRIAL OF INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS: ANALYSIS OF SAFETY, TOLERABILITY, AND 5-YEAR OUTCOME

Neuro-Oncology2022-11-01

IMMU-04. FIRST-IN-CHILDREN PHASE 1B STUDY USING THE IDO PATHWAY INHIBITOR INDOXIMOD IN COMBINATION WITH RADIATION AND CHEMOTHERAPY FOR CHILDREN WITH NEWLY DIAGNOSED DIPG (NCT02502708, NLG2105)

Neuro-Oncology2021-06-014 citations

Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer

JAMA Oncology2020-11-0544 citations

IMMU-25. RADIO-IMMUNOTHERAPY USING THE IDO PATHWAY INHIBITOR INDOXIMOD FOR CHILDREN WITH NEWLY-DIAGNOSED DIPG

Neuro-Oncology2018-06-01

Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.

Journal of Clinical Oncology2018-05-2042 citations

Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.

Journal of Clinical Oncology2018-05-2039 citations

Abstract CT117: Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma

Cancer Research2017-07-0137 citations

A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2017-05-2039 citations

Abstract CT087: Phase II trial of theiIndoleamine 2, 3-dioxygenase pathway (IDO) inhibitor indoximod plus immune checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma

Cancer Research2016-07-154 citations

Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: Interim analysis.

Journal of Clinical Oncology2016-05-2034 citations

Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.

Journal of Clinical Oncology2016-05-2022 citations

7 more papers not shown

Indoximod

Sponsors

Conditions

Phase 1

Phase 2

Related Papers